Smartleaf Asset Management’s First Tracks Biotherapeutics TRAX Stock Holding History

Smartleaf Asset Management’s Portfolio TRAX Stock Details TRAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$22.5K	Buy	+626	New	+$24.4K	﹤0.01%	2057

Other funds holding TRAX

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Sanofi Paris, France $630M AUM 104.49% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $57.2B AUM 42.49% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $179B AUM 29.92% 1-Year Est. Return

Russell Investments Group London, United Kingdom $114B AUM 33.83% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Smartleaf Asset Management's TRAX Position: Q3 2026 in Review

Smartleaf Asset Management opened a new position in First Tracks Biotherapeutics (TRAX) in Q3 2026: 626 shares worth $22.5K. The stake represents ﹤0.01% of the portfolio and ranks #2057 among its holdings.

69 funds tracked by Wall St. Rank hold TRAX as of Q3 2026.

Smartleaf Asset Management held 626 shares of First Tracks Biotherapeutics worth $22.5K as of Q3 2026.
First Tracks Biotherapeutics was a new Smartleaf Asset Management position in Q3 2026.
First Tracks Biotherapeutics made up ﹤0.01% of Smartleaf Asset Management's portfolio in Q3 2026, its #2057 holding.
69 funds tracked by Wall St. Rank held First Tracks Biotherapeutics as of Q3 2026.

Based on Smartleaf Asset Management's 13F filing for Q3 2026, filed 10 Nov 2026.